Aramark stock rises as ARMK investors digest earnings, 2026 outlook and dividend dates

February 11, 2026
Aramark stock rises as ARMK investors digest earnings, 2026 outlook and dividend dates

New York, February 11, 2026, 11:04 EST — Regular session

  • Aramark’s stock gained roughly 1.7%, reaching $41.66 in late-morning trading
  • Revenue for Q1 increased 6% to $4.83 billion, with organic growth hitting 5%, despite calendar shifts making comparisons tougher
  • Investors are focused on a potential boost from second-quarter comparisons and the dividend record date set for Feb. 18

Aramark’s shares climbed roughly 1.7% to $41.66 late Wednesday morning. Investors digested the caterer’s quarterly report while sizing up its outlook for the coming year.

This shift is significant since Aramark relies heavily on winning and renewing contracts to fuel growth. Customers in offices, campuses, healthcare, and sports venues continue to be choosy about price and service. Even a small drop in retention usually hits the stock hard.

This quarter brought a timing wrinkle that clouds the outlook. Fiscal 2025 included a 53rd week, and Aramark noted that this “calendar shift” suppressed reported growth in Q1 but is expected to boost results in Q2.

Revenue climbed 6% to $4.83 billion in the fiscal first quarter ending Jan. 2, with “organic” revenue — excluding currency effects — up 5%, the company reported. Food and Support Services U.S. sales rose 2% to $3.36 billion, while the international segment surged 17% to $1.47 billion. CEO John Zillmer highlighted “extraordinary client retention” and “significant new business” during the quarter. 1

Profit results were uneven. GAAP earnings per share dropped 8% to $0.36, but adjusted EPS—which strips out certain items—remained steady at $0.51, the company reported. Aramark reaffirmed its fiscal 2026 goals, aiming for 7% to 9% organic revenue growth and adjusted EPS between $2.18 and $2.28. It also expects its leverage ratio, a debt-to-earnings metric used in loan covenants, to dip below 3x by year-end. 2

On Tuesday, Aramark submitted an 8-K containing its earnings report for the quarter ending Jan. 2, 2026. 3

International stood out as the brightest spot, buoyed by growth in the base business and fresh accounts. The U.S. segment, however, bore the brunt of the calendar challenges. Management highlighted supply-chain efficiencies and technology investments as key moves to safeguard margins while ramping up new business.

Risks remain. The company flagged mobilization expenses in several countries as it scales up record new business, which can squeeze short-term profits despite growing revenue. Food and labor costs add another layer of uncertainty; contract resets don’t necessarily keep pace with inflation.

Investors are watching closely to find out if the second quarter’s calendar boost reveals clearer signs of real growth — and if fresh wins actually boost profits instead of just increasing volume. Another short-term focus is capital returns: Aramark announced its quarterly dividend of $0.12 per share will be paid on March 4 to shareholders recorded by Feb. 18. 4

Stock Market Today

  • Australia Hard Capsule Fill Excipients Market Analysis, Forecast to 2035
    April 3, 2026, 7:40 PM EDT. The Australia market for Hard Capsule Fill Excipients, key inactive ingredients used in pharmaceutical capsules, is analyzed in this strategic report. Covering historic data from 2012 to 2025 and forecasts to 2035, it provides insights into market size, supply chains, pricing mechanisms, and competitive dynamics. The report targets manufacturers, investors, and suppliers seeking clarity on market boundaries, demand drivers, regulatory landscape, and production challenges. It highlights critical issues like supply bottlenecks, cost drivers, and entry strategies, offering guidance on where growth opportunities and risks lie within this specialized segment of pharmaceutical ingredients.